PropertyValue
?:abstract
  • COVID-19 has rapidly become a major concern for the health systems worldwide. Its high contagiousness and associated mortality demand the discovery of helpful interventions with promising safety profile. Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor.
?:creator
?:doi
?:doi
  • 10.1159/000510179
?:journal
  • Acta_Haematol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/04d08bb5902f1d3496b018c29d7d9e35403b71e4.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7490485.xml.json
?:pmcid
?:pmid
?:pmid
  • 32726783.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients
?:type
?:year
  • 2020-07-29

Metadata

Anon_0  
expand all